Announcements
- Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
- Monopar and NorthStar Amend & Extend Collaboration
- Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
- Monopar Announces CFO Succession
- Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
More ▼
Key statistics
On Monday, Monopar Therapeutics Inc (1IY:MUN) closed at 0.67, 148.15% above the 52 week low of 0.270 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.67 |
---|---|
High | 0.67 |
Low | 0.67 |
Bid | 0.65 |
Offer | 0.69 |
Previous close | 0.67 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.48m |
Free float | 8.12m |
P/E (TTM) | -- |
Market cap | 12.59m USD |
EPS (TTM) | -0.5289 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 07:06 BST.
More ▼